- Fobi AI (FOBI) announced that its wholly-owned subsidiary, PulseIR, has signed a new deal with Empower Clinics
- Empower is an integrated healthcare provider offering a telemedicine platform for healthcare and diagnostics solutions across the U.S. and Canada
- Fobi will generate $120,000 in revenue for the one-year contract
- Fobi is an AI and data intelligence company
- Fobi AI Stock (FOBI) remains steady, trading at $0.345 per share at 10:14 am ET
Fobi AI (FOBI) announced that its wholly-owned subsidiary, PulseIR, has signed a new deal with Empower Clinics.
Empower is an integrated healthcare provider offering a telemedicine platform for healthcare and diagnostics solutions across the U.S. and Canada.
PulseIR is a platform as a service (PaaS). It made its public commercial launch on Jan 30, 2023 with its first client, PanGenomic Health Inc.
Fobi will generate $120,000 in revenue for the one-year contract. The company will recognize the revenue over the 12 months of the contract.
Rob Anson, CEO of Fobi, commented on the announcement.
“We are garnering a great deal of interest in our PulseIR services and are very well-positioned with an incredibly relevant solution stack. We are built for rapid deployment and scale and this is where things begin to gain great momentum as we continue to deliver transformative mobile solutions across various industries.”
“This second contract with Empower Clinics validates the interest and demand for public issuers that are looking to deliver personalized, automated, and data-driven mobile IR solutions to their shareholders.”
Fobi is an AI and data intelligence company. It provides businesses with real-time applications to digitally transform and future-proof their organizations.
Fobi AI (FOBI) remains steady, trading at $0.345 per share at 10:14 am ET.
